By Michael Vlessides
Originally published by our sister publication Gastroenterology & Endoscopy News
Patients with Crohn’s disease who achieve deep remission one year after combination therapy with infliximab and an immunosuppressant do not have better disease outcomes than their counterparts who do not achieve deep remission, researchers have found.
The follow-up analysis, of the TAILORIX trial, concluded that patients with and without deep remission at week 54 had comparable rates of